Mediclinic International (LON:MDC) had its price objective lowered by Barclays from GBX 460 ($6.01) to GBX 410 ($5.36) in a report released on Friday morning, ThisIsMoney.Co.Uk reports. Barclays currently has an equal weight rating on the stock.
Several other research analysts have also recently issued reports on MDC. HSBC decreased their price objective on shares of Mediclinic International from GBX 390 ($5.10) to GBX 360 ($4.70) and set a hold rating for the company in a report on Wednesday, January 16th. JPMorgan Chase & Co. upgraded shares of Mediclinic International to an overweight rating and decreased their price objective for the company from GBX 480 ($6.27) to GBX 394 ($5.15) in a report on Monday, January 7th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of GBX 428.50 ($5.60).
Mediclinic International stock opened at GBX 312.10 ($4.08) on Friday. The company has a quick ratio of 1.75, a current ratio of 1.92 and a debt-to-equity ratio of 60.35. The company has a market capitalization of $2.30 billion and a PE ratio of -3.77. Mediclinic International has a 12-month low of GBX 293.10 ($3.83) and a 12-month high of GBX 712.40 ($9.31).
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 private acute care hospitals and 4 clinics with approximately 1,805 inpatient beds in Switzerland; 49 acute care private hospitals and 2 day clinics in South Africa, and 3 hospitals in Namibia with approximately 8,131 inpatient beds; and 6 acute care private hospitals and 22 clinics with approximately 748 inpatient beds in the United Arab Emirates.
Further Reading: Momentum Investing
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.